data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Clearside Biomedical

(NASDAQ:CLSD)

Intraday

$1.42

0.05[3.65%]

15 minutes delayed

Perks Buy Compare Brokers

$1.42

0.05[3.65%]

Last update: 8:03AM Get Real Time Here

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Clearside Biomedical Stock (NASDAQ:CLSD)

Clearside Biomedical Stock (NASDAQ: CLSD)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, April 22, 2024

Expensify And 2 Other Stocks Under $2 Insiders Are Buying
Avi Kapoor - 2 days ago

Thursday, April 11, 2024

Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
Benzinga Newsdesk - Apr 11, 2024, 5:59AM

Wednesday, March 27, 2024

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Mar 27, 2024, 4:31PM

Thursday, March 14, 2024

12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights - Mar 14, 2024, 1:31PM
HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga Newsdesk - Mar 14, 2024, 6:53AM

Wednesday, March 13, 2024

JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $5 Price Target
Benzinga Newsdesk - Mar 13, 2024, 11:23AM
Wedbush Maintains Outperform on Clearside Biomedical, Lowers Price Target to $4
Benzinga Newsdesk - Mar 13, 2024, 9:31AM
Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
Benzinga Newsdesk - Mar 13, 2024, 6:29AM

Tuesday, March 12, 2024

Clearside Biomedical: Q4 Earnings Insights
Benzinga Insights - Mar 12, 2024, 4:30PM
Clearside Biomedical Q4 2023 Adj EPS $(0.08) Beats $(0.09) Estimate, Sales $6.30M Beat $4.43M Estimate
Benzinga Newsdesk - Mar 12, 2024, 4:17PM
Earnings Scheduled For March 12, 2024
Benzinga Insights - Mar 12, 2024, 5:35AM

Monday, March 11, 2024

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Mar 11, 2024, 5:34PM
Preview: Clearside Biomedical's Earnings
Benzinga Insights - Mar 11, 2024, 11:01AM

Tuesday, February 20, 2024

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights - Feb 20, 2024, 4:31PM

Wednesday, February 07, 2024

Clearside Biomedical Announces Pricing Of $15M Registered Direct Offering With Institutional Investors And An Existing Stockholder, Providing For The Purchase And Sale Of 11,111,111 Shares Of Common Stock And Accompanying Warrant
Benzinga Newsdesk - Feb 7, 2024, 8:23AM

Monday, January 22, 2024

Top 5 Health Care Stocks That May Crash This Month
Avi Kapoor - Jan 22, 2024, 7:34AM

Wednesday, January 17, 2024

Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
Vandana Singh - Jan 17, 2024, 3:28PM

Thursday, December 14, 2023

Clearside Biomedical Reports Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Benzinga Newsdesk - Dec 14, 2023, 7:07AM

Tuesday, November 14, 2023

HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga Newsdesk - Nov 14, 2023, 6:48AM

Monday, November 13, 2023

Clearside Biomedical: Q3 Earnings Insights
Benzinga Insights - Nov 13, 2023, 4:20PM
Clearside Biomedical Q3 EPS $(0.15), Inline, Sales $859.00K Beat $160.00K Estimate
Benzinga Newsdesk - Nov 13, 2023, 4:16PM
Earnings Scheduled For November 13, 2023
Benzinga Insights - Nov 13, 2023, 6:40AM

Friday, November 10, 2023

Clearside Biomedical's Earnings: A Preview
Benzinga Insights - Nov 10, 2023, 10:01AM

Monday, November 06, 2023

HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga Newsdesk - Nov 6, 2023, 6:42AM

Friday, November 03, 2023

BioCryst And Clearside Biomedical Enter Partnership To Develop Avoralstat For Diabetic Macular Edema Using Clearside's Proprietary SCS Microinjector; SCS Microinjector Is The First And Only FDA-Approved Approach To Access The Suprachoroidal Space
Benzinga Newsdesk - Nov 3, 2023, 12:02PM

Thursday, November 02, 2023

Clearside Biomedical Insider Trades Send a Signal
Benzinga Insights - Nov 2, 2023, 11:03AM
Over $2M Bet On Community Health Systems? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Lisa Levin - Nov 2, 2023, 8:12AM

Monday, October 16, 2023

Clearside Biomedical Presents OASIS And Extension Study Data At The Retina Society 56th Annual Scientific Meeting
Benzinga Newsdesk - Oct 16, 2023, 7:15AM

Thursday, October 05, 2023

Clearside Biomedical And 3 Other Stocks Under $3 Insiders Are Buying
Lisa Levin - Oct 5, 2023, 9:07AM

Wednesday, October 04, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Oct 4, 2023, 12:01PM
Clearside Biomedical Announces Advancement Of XIPERE In Asia-Pacific For Suprachoroidal Treatment Of Uveitic Macular Edema As Partner Arctic Vision Completes Enrollment In Phase 3 Clinical Trial In China
Benzinga Newsdesk - Oct 4, 2023, 9:10AM

Thursday, September 21, 2023

CEO at Clearside Biomedical Acquires Company Stock Options Worth 200,000 Shares
Benzinga Insights - Sep 21, 2023, 11:02AM
Chief Financial Officer at Clearside Biomedical Acquires Company Stock Options Worth 100,000 Shares
Benzinga Insights - Sep 21, 2023, 11:02AM

Thursday, September 14, 2023

Chief Financial Officer at Clearside Biomedical Exercises Options Worth $29K
Benzinga Insights - Sep 14, 2023, 11:00AM

Tuesday, September 12, 2023

Clearside Biomedical Granted U.S. Patent #11752101: Ocular injector and methods for accessing suprachoroidal space of the eye
Charles Gross - Sep 12, 2023, 8:20AM

Friday, September 08, 2023

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Sep 8, 2023, 1:58PM

Wednesday, September 06, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Sep 6, 2023, 2:43PM

Tuesday, August 15, 2023

JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $5 Price Target
Benzinga Newsdesk - Aug 15, 2023, 10:14AM
HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga Newsdesk - Aug 15, 2023, 6:52AM
Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
Benzinga Newsdesk - Aug 15, 2023, 6:45AM

Monday, August 14, 2023

Clearside Biomedical Q2 EPS $(0.15) Misses $(0.14) Estimate, Sales $1.02M Beat $120.00K Estimate
Benzinga Newsdesk - Aug 14, 2023, 4:11PM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Wednesday, July 19, 2023

HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga Newsdesk - Jul 19, 2023, 6:06AM

Monday, July 17, 2023

Clearside Biomedical Announces Enrollment Of Multiple Participants In Its ODYSSEY Phase 2b Clinical Trial Of CLS-AX (axitinib injectable suspension) In Wet AMD
Benzinga Newsdesk - Jul 17, 2023, 7:10AM

Wednesday, July 12, 2023

JMP Securities Reiterates Market Outperform on Clearside Biomedical, Maintains $5 Price Target
Benzinga Newsdesk - Jul 12, 2023, 9:02AM

Monday, July 10, 2023

HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga Newsdesk - Jul 10, 2023, 12:17PM
Clearside Biomedical Announced That The Therapeutic Goods Administration Of Australia Has Formally Accepted Arctic Vision's New Drug Application For Suprachoroidal Use Of Arcatus (ARVN001) For Uveitic Macular Edema
Benzinga Newsdesk - Jul 10, 2023, 7:09AM

Tuesday, June 27, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights - Jun 27, 2023, 9:12AM

Wednesday, June 14, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Benzinga Insights - Jun 14, 2023, 11:01AM
JonesTrading Initiates Coverage On Clearside Biomedical with Buy Rating, Announces Price Target of $6
Benzinga Newsdesk - Jun 14, 2023, 7:34AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved